Search results for "Prostatic neoplasm"

showing 10 items of 285 documents

Androgen receptors and hormone sensitivity of a human prostatic cancer cell line (PC-3) are modulated by natural beta-interferon.

1994

Androgen receptors are expressed at a low level in the cell line PC-3, which does not respond to either androgens or antiandrogens. If these cells are exposed to natural beta-interferon (beta-IFN) a reduction in cell growth and an increase in androgen receptors, evaluated by both biochemical and immunocytochemical techniques, occur. This increase seems not to be related to a selective block of PC-3 in any phase of the cell cycle. Pretreatment with beta-IFN determines in PC-3 cells a partial responsiveness to the androgen dihydrotestosterone as reflected by the increase in cell number. Moreover, the antiandrogen hydroxyflutamide shows agonistic properties by increasing the cell number of PC-…

Malemedicine.medical_specialtymedicine.drug_classUrologyDrug Resistanceurologic and male genital diseasesAntiandrogenchemistry.chemical_compoundInternal medicinemedicineTumor Cells CulturedHumansCell growthCell CycleProstatic NeoplasmsAndrogen AntagonistsDihydrotestosteroneInterferon-betaCell cycleAndrogenImmunohistochemistryFlutamideAndrogen receptorEndocrinologychemistryCell cultureReceptors AndrogenDihydrotestosteroneAndrogensHydroxyflutamideCell Divisionmedicine.drugUrological research
researchProduct

Natural beta-interferon and androgen receptors in prostatic cancer cells.

1991

Both PC-3 and DU-145 cell lines are androgen-insensitive, but, in our experience, they contain androgen receptors (AR). Treatment of these cells with natural beta-interferon at a concentration of 1,000 IU/ml of culture medium determines an increase of AR (evaluated by a whole-cell assay), statistically significant with respect to control. Androgen unresponsiveness of our cells could be due to an AR level which is lower than that present in hormone-sensitive prostatic cancer cell lines, such as LNCaP cells. For this reason, interferon-promoted AR increase merits further investigation, even if other defects in receptor mechanism, responsible for hormone insensitivity, cannot be excluded.

Malemedicine.medical_specialtymedicine.drug_classUrologymedicine.medical_treatmenturologic and male genital diseasesCell LineProstateInternal medicinemedicineTumor Cells CulturedHumansβ interferonbusiness.industryProstatic NeoplasmsImmunotherapyAndrogenAndrogen receptorEndocrinologymedicine.anatomical_structureCell cultureReceptors AndrogenCancer cellInterferon Type IbusinessInterferon type Imedicine.drugUrologia internationalis
researchProduct

PI-RADS 3 Lesions: Role of Prostate MRI Texture Analysis in the Identification of Prostate Cancer

2021

Abstract Purpose To determine the diagnostic performance of texture analysis of prostate MRI for the diagnosis of prostate cancer among Prostate Imaging Reporting and Data System (PI-RADS) 3 lesions. Materials and Methods Forty-three patients with at least 1 PI-RADS 3 lesion on prostate MRI performed between June 2016 and January 2019 were retrospectively included. Reference standard was pathological analysis of radical prostatectomy specimens or MRI-targeted biopsies. Texture analysis extraction of target lesions was performed on axial T2-weighted images and apparent diffusion coefficient (ADC) maps using a radiomic software. Lesions were categorized as prostate cancer (Gleason score [GS] …

Malemedicine.medical_specialtymedicine.medical_treatment030218 nuclear medicine & medical imaging03 medical and health sciencesProstate cancer0302 clinical medicineProstatemedicineHumansEffective diffusion coefficientRadiology Nuclear Medicine and imagingStatistical analysisPI-RADSRetrospective StudiesProstate cancerbusiness.industryProstatectomyProstatic NeoplasmsLinear discriminant analysismedicine.diseaseMagnetic Resonance ImagingConfidence intervalPI-RADSmedicine.anatomical_structure030220 oncology & carcinogenesisRadiologyNeoplasm GradingSettore MED/36 - Diagnostica Per Immagini E RadioterapiabusinessMRICurrent Problems in Diagnostic Radiology
researchProduct

Prediction by quantitative histology of pathological stage in prostate cancer.

2005

To find a predictor of extraprostatic extension in clinically localized prostate cancer (PCa), pre-operative ultrasound-guided prostate needle biopsies and clinico-pathological data were reviewed.One hundred and eighty-three consecutive patients who underwent radical retropubic prostatectomy for clinical T1-T2 PCa and serum PSA10 ng/ml were reviewed. Pre-operative biopsy was performed according to an extended protocol and whole-mount prostatectomy specimens were processed. The following biopsy variables were categorized to this analysis: Gleason score (or =6,6), TPC (or =20%;20%), GPC (or =50%;50%), cancer-positive cores (or =2;2), cancer-positive cores in both lateral portions (yes; no), P…

Malemedicine.medical_specialtymedicine.medical_treatmentBiopsyUrologyurologic and male genital diseasesLogistic regressionSensitivity and SpecificityProstate cancerProstatePredictive Value of TestsBiopsymedicineOdds RatioHumansStage (cooking)AgedNeoplasm Stagingmedicine.diagnostic_testbusiness.industryProstatic NeoplasmsGeneral MedicineOdds ratioMiddle AgedProstate-Specific Antigenmedicine.diseaseSurgerymedicine.anatomical_structureLogistic ModelsOncologyROC CurveMultivariate AnalysisSurgeryPositive Surgical MarginbusinessRadical retropubic prostatectomyEuropean journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
researchProduct

Is high dose rate brachytherapy reliable and effective treatment for prostate cancer patients? A review of the literature.

2014

The intrinsic physical and radiobiological characteristics of High Dose Rate Brachytherapy (HDR-BT) are well suited to the treatment of prostate cancer. HDR-BT was initially used as a boost to external beam brachytherapy, but has subsequently been employed as the sole treatment, which is termed HDR monotherapy. This review summarizes the clinical outcomes and toxicity results of the principal studies and discusses the radiobiological basis supporting its use.

Malemedicine.medical_specialtymedicine.medical_treatmentBrachytherapyBrachytherapyProstate cancermedicineEffective treatmentHumansMedical physicsDose FractionationSalvage brachytherapySalvage TherapyProstate cancerbusiness.industryRadiobiologyProstatic NeoplasmsRadiotherapy DosageHDR-BTHematologymedicine.diseaseBrachytherapy boost; HDR-BT; High-dose rate brachytherapy; Prostate cancer; Radiobiology; Salvage brachytherapy; Dose Fractionation; Humans; Male; Prostatic Neoplasms; Salvage Therapy; Treatment Outcome; Brachytherapy; Radiotherapy Dosage; Hematology; Oncology; Geriatrics and GerontologyHigh-Dose Rate BrachytherapyBrachytherapy boostTreatment OutcomeOncologyRadiologyDose Fractionation RadiationGeriatrics and GerontologybusinessHigh-dose rate brachytherapySalvage brachytherapyCritical reviews in oncology/hematology
researchProduct

Trends in Radical Prostatectomy Risk Group Distribution in a European Multicenter Analysis of 28 572 Patients: Towards Tailored Treatment

2019

Background: Active surveillance (AS) has been increasingly proposed as the preferential initial management strategy for low-risk prostate cancer (PC), while in high-risk PC the indication for surgery has widened. Objective: To evaluate the development of risk group distribution of patients undergoing radical prostatectomy (RP). Design, setting, and participants: Retrospective database review of combined RP databases (2000-2015) of four large European centers (Créteil, Paris; San Rafaele, Milan; Martini Klinik, Hamburg; NKI, AvL, Amsterdam). Outcome measurements and statistical analysis: Clinical and pathological characteristics per year of surgery. Eligibility for AS was defined according …

Malemedicine.medical_specialtymedicine.medical_treatmentUrology030232 urology & nephrologyRisk classificationDiseaseActive surveillanceRisk AssessmentTreatment trend03 medical and health sciencesProstate cancer0302 clinical medicineRisk groupsInternal medicineHumansMedicineDistribution (pharmacology)Watchful WaitingPathologicalRetrospective StudiesProstatectomyProstate cancerbusiness.industryProstatectomyProstatic NeoplasmsCancerProstate-Specific Antigenmedicine.diseaseTailored treatmentRadical prostatectomySurgeryEurope030220 oncology & carcinogenesisNeoplasm Gradingbusiness
researchProduct

Musculoskeletal Responses to Exercise Plus Nutrition in Men with Prostate Cancer on Androgen Deprivation: A 12-Month RCT

2021

PURPOSE Androgen deprivation therapy (ADT) for prostate cancer has multiple adverse effects on musculoskeletal health. This 12-month randomized controlled trial aimed to assess the effects of multicomponent exercise training combined with whey protein, calcium and vitamin D supplementation on bone mineral density (BMD), structure and strength, body composition, muscle strength, and physical function in ADT-treated men. METHODS Seventy ADT-treated men were randomized to exercise plus supplementation (Ex + Suppl; n = 34) or usual care (control; n = 36). Ex + Suppl involved thrice weekly progressive resistance training plus weight-bearing impact exercise with daily multinutrient supplementatio…

Malemedicine.medical_specialtymusclelihaksetPhysical Therapy Sports Therapy and Rehabilitationandrogen deprivation therapybonelaw.inventionravintoAndrogen deprivation therapyProstate cancerRandomized controlled trialBone DensitylawInternal medicinemedicinecancerHumansOrthopedics and Sports MedicineMuscle StrengthVitamin DAdverse effectAgedFemoral neckBone mineralluustoexercisesyöpähoidoteturauhassyöpäkuntoliikuntabusiness.industryProstatic NeoplasmsAndrogen Antagonistsmedicine.diseaseConfidence intervalExercise TherapyCalcium DietarynutritionWhey Proteinsmedicine.anatomical_structureDietary SupplementsBody CompositionLean body massPatient CompliancesyöpätauditbusinessBiomarkersMedicine & Science in Sports & Exercise
researchProduct

Choline PET/CT Features to Predict Survival Outcome in High Risk Prostate Cancer Restaging: A Preliminary Machine-Learning Radiomics Study

2020

Background Radiomic features are increasingly utilized to evaluate tumor heterogeneity in PET imaging but to date its role has not been investigated for Cho-PET in prostate cancer. The potential application of radiomics features analysis using a machine-learning radiomics algorithm was evaluated to select 18F-Cho PET/CT imaging features to predict disease progression in PCa. Methods We retrospectively analyzed high-risk PCa patients who underwent restaging 18F-Cho PET/CT from November 2013 to May 2018. 18F-Cho PET/CT studies and related structures containing volumetric segmentations were imported in the "CGITA" toolbox to extract imaging features from each lesion. A Machine-learning model h…

Malemedicine.medical_specialtyn artificial intelligence model demonstrated to be feasible and able to select a panel of 18F-Cho PET/CT features with valuable association with PCa patients' outcome.business.industryProstatic NeoplasmsFeature selectionPet imagingCholine pet ctmedicine.diseaseTumor heterogeneitySurvival outcomeCholineMachine LearningProstate cancerRadiomicsFeature (computer vision)Artificial IntelligencePositron Emission Tomography Computed TomographyMedicineHumansRadiology Nuclear Medicine and imagingRadiologybusinessRetrospective Studies
researchProduct

Multiparametric MRI and post implant CT-based dosimetry after prostate brachytherapy with iodine seeds: The higher the dose to the dominant index les…

2015

Abstract Purpose To determine whether post-implant MRI-based dosimetry of the Dominant Intra-prostatic Lesion (DIL) could best predict the occurrence of PSA bounce after prostate brachytherapy. Methods and materials We selected 66 patients with a low risk prostate cancer treated with 125 I prostate brachytherapy as monotherapy. Post-implant dosimetry based on day 30 CT-scan and multiparametric MRI co-registration was generated: planned D 90, D 95, V 100, V 150 values were calculated for each DIL. Bounce was defined as a PSA elevation ⩾0.2ng/mL from the previous baseline value followed by a decrease to or below the prior nadir with no additional treatment. Results After a median follow-up of…

Malemedicine.medical_treatmentBrachytherapyBrachytherapyIodine RadioisotopesProstate cancerProstatemedicineHumansDosimetryRadiology Nuclear Medicine and imagingRadiometryAgedRetrospective StudiesIndex Lesionmedicine.diagnostic_testbusiness.industryProstateProstatic NeoplasmsRadiotherapy DosageMagnetic resonance imagingHematologyMiddle AgedProstate-Specific Antigenmedicine.diseaseMagnetic Resonance ImagingProstate-specific antigenTreatment Outcomemedicine.anatomical_structureOncologyTomography X-Ray ComputedNuclear medicinebusinessProstate brachytherapyFollow-Up StudiesRadiotherapy and Oncology
researchProduct

Neuromodulation of the superior hypogastric plexus: a new option to treat bladder atonia secondary to radical pelvic surgery?

2009

Abstract Background The aim of this study is to report on the impact of neuromodulation to the superior hypogastric plexus in patients with bladder atonia secondary to pelvic surgery. Methods In 4 consecutive patients with bladder atonia secondary to pelvic surgery, we performed a laparoscopic implantation of a neurostimulator—LION procedure—to the entire superior hypogastric plexus. Results Of the 4 reported patients, 3 are able to partially void or empty their bladder. Conclusions If the presented results could be obtained in further patients and maintained in long-term follow-up, the LION procedure to the superior hypogastric plexus could change the management of bladder function in pati…

Malemedicine.medical_treatmentEndometriosisurologic and male genital diseasesColonic DiseasesPostoperative ComplicationsMedicineLaparoscopyUrinary bladdermedicine.diagnostic_testProstatectomyHypogastric PlexusBladder atoniaEquipment DesignMiddle Agedfemale genital diseases and pregnancy complicationsPain IntractableBladder atonia; LION procedure; Superior hypogastric plexusmedicine.anatomical_structureFemaleSuperior hypogastric plexumedicine.symptomSuperior hypogastric plexusAdultmedicine.medical_specialtyUrinary BladderEndometriosisElectric Stimulation TherapyCauda equineHysterectomyPelvic Painmedicine.nerveSuperior hypogastric plexusHumansUrinary Bladder NeurogenicSpina bifidaProstatectomyHypogastric PlexusHysterectomybusiness.industryPelvic painProstatic Neoplasmsmedicine.diseaseSettore MED/40 - Ginecologia E OstetriciaEndometrial NeoplasmsSurgeryUrodynamicsRectal DiseasesLION procedureLaparoscopySurgeryNeurology (clinical)businessGenital Diseases FemaleFollow-Up Studies
researchProduct